Abstract
Fanconi anemia (FA) is a disorder characterized by developmental anomalies, bone marrow failure and a predisposition to malignancy. It has recently been shown that hematopoietic stem cell transplantation using fludarabine (FLU)-based reduced-intensity conditioning is an efficient and quite safe therapeutic modality. We retrospectively analyzed the outcome of bone marrow transplantation (BMT) in eight patients with FA performed in two institutes between 2001 and 2011. There were seven females and one male with a median age at diagnosis = 4.5 years (range 2–12 years). The constitutional characteristics associated with FA, such as developmental anomalies, short stature and skin pigmentation, were absent in three of the patients. One patient showed myelodysplastic features at the time of BMT. All patients received BMT using FLU, cyclophosphamide (CY) and rabbit anti-thymocyte globulin (ATG) either from a related donor (n = 4) or an unrelated donor (n = 4). Acute graft-versus-host disease (GVHD) of grade I developed in one patient, while chronic GVHD was not observed in any patient. All patients are alive and achieved hematopoietic recovery at a median follow-up of 72 months (range 4–117 months). BMT using FLU/low-dose CY/ATG -based regimens regardless to the donor is a beneficial therapeutic approach for FA patients.
Similar content being viewed by others
References
Fanconi G. Familial constitutional panmyelocytopathy, Fanconi’s anemia (F.A.). I. Clinical aspects. Semin Hematol. 1967;4:233–40.
Alter BP. Fanconi’s anemia and malignancies. Am J Hematol. 1996;53:99–110.
Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, Hanenberg H, Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249–56.
Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010;24:101–22.
Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009;668:4–10.
Yabe M, Yabe H, Hamanoue S, Inoue H, Matsumoto M, Koike T, Ishiguro H, Morimoto T, Arakawa S, Ohshima T, Masukawa A, Miyachi H, Yamashita T, Katob S. In vitro effect of fludarabine, cyclophosphamide, and cytosine arabinoside on chromosome breakage in Fanconi anemia patients: relevance to stem cell transplantation. Int J Hematol. 2007;85(4):354–61.
Yabe H, Inoue H, Matsumoto M, Hamanoue S, Koike T, Ishiguro H, Koike H, Suzuki K, Kato S, Kojima S, Tsuchida M, Mori T, Adachi S, Tsuji K, Koike K, Morimoto A, Sako M, Yabe M. Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia. Br J Haematol. 2006;134:208–12.
MacMillan ML, Wagner JE. Haematopoietic cell transplantation for Fanconi anaemia—when and how? Br J Haematol. 2010;149:14–21.
Gluckman E, Berger R, Dutreix J. Bone marrow transplantation for Fanconi anemia. Semin Hematol. 1984;21:20–6.
Kapelushnik J, Or R, Slavin S, Nagler A. A fludarabine-based protocol for bone marrow transplantation in Fanconi’s anemia. Bone Marrow Transplant. 1997;20:1109–10.
Dalle JH. HSCT for Fanconi anemia in children: factors that influence early and late results. Bone Marrow Transplant. 2008;42:S51–3.
Chaudhury S, Auerbach AD, Kernan NA, Small TN, Prockop SE, Scaradavou A, Heller G, Wolden S, O’Reilly RJ, Boulad F. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol. 2008;140:644–55.
Gluckman E, Auerbach AD, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM, Butturini A, Camitta BM, Champlin RE, Friedrich W, Good RA, Gordon-Smith EC, Harris RE, Klein JP, Ortega JJ, Pasquini R, Ramsay NK, Speck B, Vowels MR, Zhang MJ, Gale RP. Bone marrow transplantation for Fanconi anemia. Blood. 1995;86:2856–62.
Rosenberg PS, Socié G, Alter BP, Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood. 2005;105:67–73.
Masserot C, Peffault de Latour R, Rocha V, Leblanc T, Rigolet A, Pascal F, Janin A, Soulier J, Gluckman E, Socié G. Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. Cancer. 2008;113:3315–22.
MacMillan ML, Blazar BR, DeFor TE, Dusenbery K, Wagner JE. Thymic shielding (TS) in recipients of total body irradiation (TBI) and alternative donor hematopoietic stem cell transplant (AD-HSCT): reduced risk of opportunistic infection in patients with Fanconi anemia (FA). Blood. 2006;108 (abstract #3134).
Acknowledgments
This work was supported in part by grant for scientific research by the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Shimada, A., Takahashi, Y., Muramatsu, H. et al. Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen. Int J Hematol 95, 675–679 (2012). https://doi.org/10.1007/s12185-012-1079-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-012-1079-9